High-throughput metabolomic analysis predicts mode of action of uncharacterized antimicrobial compounds.
Ontology highlight
ABSTRACT: Rapidly spreading antibiotic resistance and the low discovery rate of new antimicrobial compounds demand more effective strategies for early drug discovery. One bottleneck in the drug discovery pipeline is the identification of the modes of action (MoAs) of new compounds. We have developed a rapid systematic metabolome profiling strategy to classify the MoAs of bioactive compounds. The method predicted MoA-specific metabolic responses in the nonpathogenic bacterium Mycobacterium smegmatis after treatment with 62 reference compounds with known MoAs and different metabolic and nonmetabolic targets. We then analyzed a library of 212 new antimycobacterial compounds with unknown MoAs from a drug discovery effort by the pharmaceutical company GlaxoSmithKline (GSK). More than 70% of these
SUBMITTER: Zampieri M
PROVIDER: S-EPMC6544516 | biostudies-literature | 2018 Feb
REPOSITORIES: biostudies-literature
ACCESS DATA